Table 5.
Association of psoriasis with incidence of type 2 diabetes in confirmed cases of psoriasis (NHS II)
| Sensitivity analysis | Diabetes cases | Person-years | Age-adjusted RR (95% CI) | Multivariate RR 1 (95% CI) |
|---|---|---|---|---|
| NHS For all participants | ||||
| No psoriasis | 4,198 | 725,208 | 1.00 | 1.00 |
| Psoriasis | 82 | 10,456 | 1.33 (1.07–1.66) | 1.14 (0.92–1.42) |
| For participants younger than 60 y | ||||
| No psoriasis | 738 | 166,169 | 1.00 | 1.00 |
| Psoriasis | 18 | 2,321 | 1.73 (1.08–2.76) | 1.40 (0.87–2.23) |
| NHS II | ||||
| No psoriasis | 3,891 | 1,483,100 | 1.00 | 1.00 |
| psoriasis | 77 | 13,768 | 1.92 (1.53–2.40) | 1.46 (1.16–1.83) |
Abbreviations: CI, confidence interval; RR, relative risk.
Simultaneously adjusted for age, body mass index (<21.0, 21.0–22.9, 23.0–24.9, 25.0–26.9, 27.0–29.9, 30.0–32.9, 33.0–34.9, 35.0–39.9 or ≥40.0 kg/m2), smoking (never, past, current with 1–14, 15–24 or ≥25 cigarettes/day), alcohol intake (no, <4.9, 5.0–14.9 or ≥15.0 g/d), physical activity (<3.0, 3.0–8.9, 9.0–17.9, 18.0–26.9 or ≥27.0 metabolic equivalent hours/wk), race (Caucasian, Asian, Hispanic or African American), family history of diabetes (yes or no), hypertension (yes or no), hypercholesterolemia (yes or no), current aspirin use (yes or no), multi-vitamin use (yes or no), postmenopausal hormone use (premenopause, never, current or past users).